Recent tariff changes and trade frictions have disrupted that advantage and slowed growth. However, CETTIRE’s flexible, low-cost structure suggests its core model remains intact, leaving the company with meaningful long-term profit potential despite the current uncertainty around customer growth and demand.
Breville is a premium global small‑appliances brand leveraging coffee leadership, innovation and an asset‑light model to drive ~10% growth. Strong cash flow, balance sheet improvement and a growing Beanz ecosystem support a justified valuation premium despite tariff pressure.
We believe Collins Foods (ASX: CKF) is entering a multi-year earnings recovery cycle anchored by margin repair in Australia, operational rejuvenation in Europe, clear line-of-sight to double-digit EBITDA growth, and an improving balance sheet that gives management options rather than constraints. The HY26 results demonstrate that CKF is moving decisively out of the inflation shock period that suppressed margins and elevated operating costs between 2022–2024. With commodity and utilities inflation easing, labour efficiencies improving, and price/mix still resilient, we see structural tailwinds forming beneath the company’s operating base.
Bega Group has evolved from a regional dairy co-operative into a diversified branded food business spanning cheese, spreads and milk beverages, combining defensive staple demand with branded exposure. The investment case now hinges on whether recent operational improvements can translate scale and strong household brands into sustained margin and ROIC expansion. However, with limited product innovation and rising marketing spend largely aimed at defending shelf space, the company’s growth profile remains more defensive than structurally transformative.
Treasury Wine Estates shows early reversal signs after a downturn, supported by restructuring optimism and stabilising demand. Key upside lies around A$5.30–A$5.70, with further gains possible if momentum holds, though sustained strength is needed to confirm a broader recovery.
The small-cap medical-tech company, Control Bionics, has just taken steps that could catapult it far beyond its current size. Its core product, a wearable sensor that translates even the faintest muscle or nerve signals into computer commands, is already approved and helps people with severe physical disabilities communicate and interact. Recently, the company announced that it had integrated a significant tech giant’s brain-computer interface protocol into its devices.
